FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 318:7-11 January 7, 1988 Number 1 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Although kidney enlargement occurs in Type I glycogen storage disease, renal disease has not been considered a major problem. Death from renal failure in three patients known to us prompted a study of renal function in this disorder. Of the 38 patients with Type I glycogen storage disease under our care, the 18 children under 10 years old had normal renal function. Fourteen of the 20 older patients (13 to 47 years) had disturbed renal function, manifested by persistent proteinuria; many also had hypertension, hematuria, or altered creatinine clearance. Progressive renal insufficiency developed in 6 of these 14 patients, leading to three deaths from renal failure. At the onset of proteinuria, creatinine clearance was increased in seven patients (3.05 +/- 0.68 ml per second per 1.73 m2 of body-surface area; range, 2.47 to 4.13 [normal range, 1.33 to 2.33 ml per second per 1.73 m2]). Renal biopsies were performed in three patients after an average of 10 years of proteinuria. All three biopsies demonstrated focal segmental glomerulosclerosis in various stages of progression. Our data suggest that chronic renal disease is a frequent and potentially serious complication of Type I glycogen storage disease. In addition to treating hypoglycemia vigorously, physicians should monitor renal function carefully in patients with this disorder.

Source Information

Department of Pediatrics, Duke University Medical Center, Durham, NC 27710.

This article has been cited by other articles:

• Martens, D. H. J., Rake, J. P., Navis, G., Fidler, V., van Dael, C. M. L., Smit, G. P. A. (2009). Renal Function in Glycogen Storage Disease Type I, Natural Course, and Renopreservative Effects of ACE Inhibition. CJASN 4: 1741-1746 [Abstract] [Full Text]  
• Leow, M. K., Bueno, C., Trivedi, N., Parmar, M. S., Oh, J., Won, H. Y., Kang, S.-M., Hebert, L. A., Rovin, B., Feig, D. I., Johnson, R. J. (2009). Uric Acid and Cardiovascular Risk. NEJM 360: 538-541 [Full Text]  
• Sun, M.-S., Pan, C.-J., Shieh, J.-J., Ghosh, A., Chen, L.-Y., Mansfield, B. C., Ward, J. M., Byrne, B. J., Chou, J. Y. (2002). Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice. Hum Mol Genet 11: 2155-2164 [Abstract] [Full Text]  
• Kishnani, P. S., Faulkner, E., VanCamp, S., Jackson, M., Brown, T., Boney, A., Koeberl, D., Chen, Y.-T. (2001). Canine Model and Genomic Structural Organization of Glycogen Storage Disease Type Ia (GSD Ia). Veterinary Pathology 38: 83-91 [Abstract] [Full Text]  
• Ringel, S. P. (1996). Future neurology workforce: The right kind and number of neurologists. Neurology 46: 897-900 [Full Text]  
• Barnett, H. J.M., Eliasziw, M., Meldrum, H. E., Taylor, D. W. (1996). Do the facts and figures warrant a 10-fold increase in the performance of carotid endarterectomy on asymptomatic patients?. Neurology 46: 603-608 [Full Text]  
• Brix, A. E., Howerth, E. W., McConkie-Rosell, A., Peterson, D., Egnor, D., Wells, M. R., Chen, Y. T. (1995). Glycogen Storage Disease Type Ia in Two Littermate Maltese Puppies. Veterinary Pathology 32: 460-465 [Abstract]